PPD Aandeel

PPD Goodwill

Delisted·9 dec 2021

De Goodwill van PPD (PPD) per 7 aug 2026 bedraagt 1,82 Miljard USD. In het voorgaande jaar bedroeg Goodwill 1,76 Miljard USD — een verandering van 3,18% (hoger).

Goodwill

1,82 MiljardUSD

YoY

3,18%

Laatst bijgewerkt:

Goodwill van PPD is 2026 1,82 Miljard USD. Goodwill van PPD was 2025 1,76 Miljard USD. Het is daarmee 3,18% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

PPD Aandelenanalyse

Wat doet PPD? PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs. PPD is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel PPD

Goodwill van PPD bedraagt 1,82 Miljard USD in 2026.

Goodwill van PPD is veranderd van 1,76 Miljard USD naar 1,82 Miljard USD, wat een verandering van 3,18% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Goodwill PPD sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

Goodwill is de premie die wordt betaald boven de reële marktwaarde bij een overname.

USD van Goodwill is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Balans — PPD

Alle kengetallen — PPD